<DOC>
	<DOCNO>NCT00629317</DOCNO>
	<brief_summary>The aim study determine efficacy MAL + Aktilite versus placebo + Aktilite facial photodamage randomize double blind trial .</brief_summary>
	<brief_title>Trial Methyl Aminolevulinate Plus Aktilite Facial Photodamage</brief_title>
	<detailed_description>It demonstrate photodamage lead wrinkle , mottle pigmentation , lentigo , telangiectasias , textural change , importantly , also lead pre-cancerous condition development actinic keratosis ( AK ) . The majority photorejuvenation photodamaged publish study use 5-Amino-Levulinic acid ( 5-ALA ) photosensitizer , either blue light Intense Pulsed Light source 70 % -95 % global facial skin improvement . The molecular mechanism improvement unknown , activation non-specific immune response addition increase fibrosis new collagen formation , suggest . Methyl Aminolevulinate ( MAL ) another market photosensitizer mainly utilized Europe . Lipophilicity , high penetration depth tumor selectivity advocate MAL compare 5-ALA . However , effect photodamaged skin well document . The aim study determine efficacy MAL + Aktilite ( PDT ) facial photodamage . Study Type : Interventional Study Design : Randomized , double-Blind , placebo-controlled trial . Official Title : A randomized , double-Blind , placebo-controlled trial Methyl Aminolevulinate + Aktilite patient facial photodamage .</detailed_description>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<mesh_term>Methyl 5-aminolevulinate</mesh_term>
	<criteria>Female subject older 35 year age less 75 year age Subjects photodamage grade 2 3 accord modify DoverÂ´s Global photodamage scale Subjects willing participate accord protocol requirement . Patients sign Informed Consent Patients exclusion criterion Pregnant nursing female . Subjects suspect porphyria , Systemic cutaneous erythematosus lupus , photosensitize disorder drug induce photosensitization . Any active infectious skin disorder ( Herpes simplex , molluscum contagiosum , facial wart ) Subjects less 6 month previous rejuvenation interfere treatment Subjects require concurrent treatment would interfere study objective and/or assessment .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Skin Aging</keyword>
	<keyword>Rejuvenation</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Methyl Aminolevulinate</keyword>
</DOC>